GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaRoth Labs Inc (GREY:ROTH) » Definitions » Debt-to-EBITDA

PharmaRoth Labs (PharmaRoth Labs) Debt-to-EBITDA : 0.00 (As of Mar. 2011)


View and export this data going back to 2008. Start your Free Trial

What is PharmaRoth Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PharmaRoth Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.00 Mil. PharmaRoth Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2011 was $0.00 Mil. PharmaRoth Labs's annualized EBITDA for the quarter that ended in Mar. 2011 was $-0.39 Mil. PharmaRoth Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2011 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PharmaRoth Labs's Debt-to-EBITDA or its related term are showing as below:

ROTH's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.43
* Ranked among companies with meaningful Debt-to-EBITDA only.

PharmaRoth Labs Debt-to-EBITDA Historical Data

The historical data trend for PharmaRoth Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaRoth Labs Debt-to-EBITDA Chart

PharmaRoth Labs Annual Data
Trend Jun08 Jun09 Jun10
Debt-to-EBITDA
- - -12.50

PharmaRoth Labs Quarterly Data
Mar07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -12.50 - -6.25 -

Competitive Comparison of PharmaRoth Labs's Debt-to-EBITDA

For the Biotechnology subindustry, PharmaRoth Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaRoth Labs's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaRoth Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PharmaRoth Labs's Debt-to-EBITDA falls into.



PharmaRoth Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PharmaRoth Labs's Debt-to-EBITDA for the fiscal year that ended in Jun. 2010 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0.25) / -0.02
=-12.50

PharmaRoth Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2011 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.392
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2011) EBITDA data.


PharmaRoth Labs  (GREY:ROTH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PharmaRoth Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PharmaRoth Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaRoth Labs (PharmaRoth Labs) Business Description

Traded in Other Exchanges
N/A
Address
8250 West Charleston Boulevard, Suite 110, Las Vegas, NV, USA, 89117
PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

PharmaRoth Labs (PharmaRoth Labs) Headlines